Since PEDF expression was dramatically reduced in endocrine-resistant breast cancer cells, we next determined whether there was a clinical correlation between PEDF expression and the development of endocrine resistance in breast tumors. This evidence concerns the gene SERPINF1 and breast carcinoma.